The news is directly about Karyopharm Therapeutics. While the 'Outperform' rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term stock price. However, the overall impact is neutral as the 'Outperform' rating suggests that the stock is still expected to do better than the market.